ASCO 2015 Highlights

Orlando, FL—Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.

Orlando, FL—Immunotherapy is now an established option for patients with non–small-cell lung cancer (NSCLC) in the second-line setting and in selected patients in the first-line setting.

Orlando, FL—The National Comprehensive Cancer Network (NCCN) has provided guidance for the clinical management of genetic mutation carriers who are identified using multigene panels without endorsing the routine use of these tests outside of research and/or intensive counseling on the risks and benefits of their use.

Implementing clinical pathways for the management of patients with metastatic non–small-cell lung cancer (NSCLC) led to a dramatic reduction in the total cost of care, while maintaining clinical outcomes, according to a study of 370 patients with NSCLC conducted at Dana-Farber Cancer Institute in Boston.

A brief overview of cancer drugs approved by the FDA between March 15, 2017, and May 30, 2017.

Orlando, FL—Molecular analysis and PD ligand 1 (PD-L1) testing for patients with non–small-cell lung cancer (NSCLC) are critically important. Optimally, multiple biomarker testing should be done at diagnosis, but it also has value before choosing therapy for second-line or later.

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.